ResMed refines APAP therapy for women
ResMed (ASX:RMD) has co-developed a new algorithm for providing auto-adjusting positive airway pressure (APAP) therapy that has been designed specifically for female sleep apnoea patients.
The company has presented research showing that the proportion of flow-limited breaths was significantly lower with the new algorithm than with standard APAP therapy.
The research, presented at the American Thoracic Society 2014 International Conference, also found a lower mean mask pressure while using the new algorithm.
The algorithm was developed by the University of Western Australia, the Western Australian Sleep Disorders Research Institute and the ResMed Science Centre.
It was designed to reflect the fact that female sleep apnoea patients typically experience shorter respiratory events than men; female apnoea occurs mainly during REM sleep cycles; and air flow is often constrained but not blocked altogether.
“The overlooked gender differences of sleep apnoea can make treatment uncomfortable and less effective for women,” ResMed vice president for medical affairs Dr Jeff Armitstead said.
“As we learn more about the condition and seek to improve ways to treat it, gender-specific approaches are an obvious next step.”
ResMed (ASX:RMD) shares were trading 1.46% lower at $5.39 as of around 1.30 pm on Friday.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
